Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)”

85 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 85 results

Early research (Phase 1)Study completedNCT00049712
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

Who this might be right for
LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
University of Wisconsin, Madison
Large-scale testing (Phase 3)Study completedNCT00003687
What this trial is testing

Treatment for Chronic Pain in Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+6 more
NCIC Clinical Trials Group 87
Early research (Phase 1)Study completedNCT00352443
What this trial is testing

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
SWOG Cancer Research Network 66
Early research (Phase 1)UnknownNCT05415098
What this trial is testing

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Who this might be right for
Nasopharyngeal CarcinomaCastrate Resistant Prostate CancerGastric Cancer+6 more
Ascentage Pharma Group Inc. 90
Early research (Phase 1)Study completedNCT00083213
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Early research (Phase 1)Ended earlyNCT00003567
What this trial is testing

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Brain and Central Nervous System TumorsLymphomaUnspecified Adult Solid Tumor, Protocol Specific
Case Comprehensive Cancer Center 8
Early research (Phase 1)Study completedNCT00019513
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

Who this might be right for
Colorectal CancerEsophageal CancerExtrahepatic Bile Duct Cancer+7 more
National Institutes of Health Clinical Center (CC) 108
Testing effectiveness (Phase 2)Study completedNCT03213691
What this trial is testing

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+8 more
National Cancer Institute (NCI) 21
Early research (Phase 1)Looking for participantsNCT05892718
What this trial is testing

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Who this might be right for
Advanced Solid TumorRefractory Non-Hodgkin Lymphoma
FBD Biologics Limited 80
Early research (Phase 1)Study completedNCT00088868
What this trial is testing

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

Who this might be right for
LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC) 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03698994
What this trial is testing

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing Sarcoma+33 more
National Cancer Institute (NCI) 20
Early research (Phase 1)Study completedNCT00876122
What this trial is testing

GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Who this might be right for
Non-Hodgkin's Lymphoma, Solid Cancers
Genentech, Inc. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213704
What this trial is testing

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor+30 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Study completedNCT03213665
What this trial is testing

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
National Cancer Institute (NCI) 20
Early research (Phase 1)Ended earlyNCT02110563
What this trial is testing

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Who this might be right for
Solid TumorsMultiple MyelomaNon-Hodgkins Lymphoma+3 more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 50
Testing effectiveness (Phase 2)Looking for participantsNCT07222631
What this trial is testing

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

Who this might be right for
Non Hodgkin LymphomaSolid Tumor
University of California, San Diego 48
Early research (Phase 1)Study completedNCT03707093
What this trial is testing

Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Who this might be right for
Solid Tumors, Non-Hodgkin Lymphoma
Adagene Inc 49
Early research (Phase 1)Study completedNCT00089271
What this trial is testing

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Who this might be right for
Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue+47 more
National Cancer Institute (NCI) 60
Early research (Phase 1)Ended earlyNCT01296555
What this trial is testing

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Who this might be right for
Solid CancersNon-Hodgkin's Lymphoma
Genentech, Inc. 674
Early research (Phase 1)Study completedNCT01588678
What this trial is testing

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Advanced Solid TumorLymphoma
Daiichi Sankyo 32
Load More Results